CONFERENCE UPDATE: ENDO 2021
Teprotumumab for the treatment of active thyroid eye disease
30 Apr 2021
Related Articles
Teprotumumab: An effective first FDA-approved treatment for thyroid eye disease regardless of age and gender
A new study accepted for presentation at the Endocrine Society’s Annual Meeting 2020 (ENDO 2020) is detailing the impact of teprotumumab on proptosis across a variety of age-, gender-, and risk factor-based subgroups.1,2
29 Jun 2020
